Taysha Gene Therapies Inc
Company Profile
Business description
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.
Contact
3000 Pegasus Park Drive
Suite 1430
DallasTX75247
USAT: +1 214 612-0000
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
99
Stocks News & Analysis
stocks
Higher fair value for undervalued wide moat share
stocks
Fears of deteriorating loan quality sends bank share plummeting
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,026.90 | 46.30 | 0.52% |
| CAC 40 | 8,381.76 | 3.11 | -0.04% |
| DAX 40 | 24,708.25 | 37.03 | 0.15% |
| Dow JONES (US) | 51,876.11 | 44.51 | -0.09% |
| FTSE 100 | 10,507.13 | 0.89 | -0.01% |
| HKSE | 23,026.68 | 354.82 | 1.57% |
| NASDAQ | 25,297.62 | 60.99 | -0.24% |
| Nikkei 225 | 69,468.11 | 107.23 | 0.15% |
| NZX 50 Index | 13,545.56 | 50.32 | 0.37% |
| S&P 500 | 7,354.02 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,823.40 | 46.50 | 0.53% |
| SSE Composite Index | 4,073.90 | 46.64 | 1.16% |